Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Flu vaccination

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE to treat advanced breast cancer

BRCA1 and BRCA2 mutations are responsible for 52% and 32% of hereditary breast cancer cases, respectively

- PMLiVE

AstraZeneca’s Tagrisso granted EC approval in EGFR-mutated lung cancer

More than 450,000 people are diagnosed with lung cancer each year in Europe

- PMLiVE

AstraZeneca’s Imfinzi granted FDA approval in limited-stage small cell lung cancer

Small cell lung cancer accounts for approximately 15% of all lung cancer diagnoses

- PMLiVE

ICR study reveals how PARP inhibitor resistance develops in prostate cancer patients

The research could pave the way for the development of new drugs that prevent drug resistance

- PMLiVE

AstraZeneca appoints Iskra Reic as executive vice president international

Reic has been serving as executive vice president of the company's vaccines and immune therapies unit

- PMLiVE

UK researchers uncover first new asthma and COPD attack treatment in 50 years

The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

- PMLiVE

AstraZeneca announces positive results for Truqap in phase 3 prostate cancer study

More than 52,000 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

AstraZeneca announces $3.5bn US investment to boost research and manufacturing

The commitment is part of the company’s ambition to achieve $80bn in total revenue by 2030

- PMLiVE

AstraZeneca/Merck’s Koselugo shows promise in adults with neurofibromatosis type 1

The rare genetic condition affects an estimated 1.7 million people globally

Daiichi Sankyo logo

Daiichi Sankyo enters $300m licensing deal with Alteogen to develop subcutaneous Enhertu

The company will use Alteogen’s hybrozyme technology to advance the formulation

- PMLiVE

AstraZeneca/Amgen’s Tezspire shows promise in phase 3 CRSwNP trial

The severe asthma drug met both of the late-stage study’s co-primary endpoints

- PMLiVE

AstraZeneca’s Fasenra approved by EC to treat rare inflammatory disease EGPA

Eosinophilic granulomatosis with polyangiitis affects approximately 118,000 people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links